Simfibrate

Severe hepatic impairment; hypoalbuminaemia; primary biliary cirrhosis; gallbladder disease; pregnancy; lactation.

Renal impairment; discontinue if myotoxicity is suspected or creatine kinase concentration increases significantly. May increase lithogenic index.

Anorexia; nausea; gastric discomfort; headache; dizziness; vertigo; fatigue; skin reactions; alopoecia; impotence; anaemia; leucopenia; myotoxicity; thrombocytopenia.

May enhance the effects of oral anticoagulants. May alter glucose tolerance in diabetics, thus dosage of antidiabetics may need to be adjusted. Concurrent admin with ciclosporin may lead to increased ciclosporin concentrations and renal toxicity.
Potentially Fatal: Increased risk of myopathy when used with statins.

Raised serum aminotransferase and creatine phosphokinase concentrations.

Description:
Mechanism of Action: Simfibrate is a fibric acid derivative that is used in the treatment of hyperlipidaemias.

Thuốc trị rối loạn lipid máu